ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

ClinicalTrials.gov ID: NCT03466099

Public ClinicalTrials.gov record NCT03466099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment

Study identification

NCT ID
NCT03466099
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Enrollment
129 participants

Conditions and interventions

Interventions

  • KVD001 Injection Drug
  • Sham Procedure Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 15, 2018
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Last update posted
Jan 27, 2021

2018 – 2019

United States locations

U.S. sites
35
U.S. states
14
U.S. cities
31
Facility City State ZIP Site status
KalVista Investigative Site Phoenix Arizona 85021
KalVista Investigative Site Phoenix Arizona 85053
KalVista Investigative Site Tucson Arizona 85704
KalVista Investigative Site Arcadia California 91007
KalVista Investigative Site Beverly Hills California 90211
KalVista Investigative Site Palm Desert California 92260
KalVista Investigative Site Palo Alto California 94303
KalVista Investigative Site Sacramento California 95819
KalVista Investigative Site Santa Ana California 92705
KalVista Investigative Site Tustin California 92780
KalVista Investigative Site Golden Colorado 80401
KalVista Investigative Site Fort Myers Florida 33912
KalVista Investigative Site Miami Florida 33126
KalVista Investigative Site Miami Florida 33143
KalVista Investigative Site Pensacola Florida 32503
KalVista Investigative Site Winter Haven Florida 33880
KalVista Investigative Site Augusta Georgia 30909
KalVista Investigative Site Marietta Georgia 30060
KalVista Investigative Site Indianapolis Indiana 46290
KalVista Investigative Site Boston Massachusetts 02114
KalVista Investigative Site Boston Massachusetts 02215
KalVista Investigative Site Henderson Nevada 89052
KalVista Investigative Site Lynbrook New York 11563
KalVista Investigative Site Rochester New York 14459
KalVista Investigative Site Cincinnati Ohio 45219
KalVista Investigative Site Rapid City South Dakota 57701
KalVista Investigative Site Abilene Texas 79606
KalVista Investigative Site Arlington Texas 76012
KalVIsta Investigative Site Austin Texas 78705
KalVista Investigative Site Dallas Texas 75231
KalVista Investigative Site Fort Worth Texas 76102
KalVista Investigative Site San Antonio Texas 78240-1502
KalVista Investigative Site San Antonio Texas 78240
KalVista Investigative Site Charlottesville Virginia 22903
KalVista Investigative Site Silverdale Washington 98383

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03466099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2021 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03466099 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →